Adagio Therapeutics, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 226.79 million. Basic loss per share from continuing operations was USD 5.32.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.15 USD | +3.86% | -6.52% | -45.43% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.43% | 247M | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- IVVD Stock
- News Invivyd, Inc.
- Adagio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021